Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. is making significant strides in developing innovative immunotherapies, evidenced by its favorable safety profile in early studies of WTX-330 and promising preclinical results from its INDUKINE programs, WTX-712 and WTX-518, which demonstrated monotherapy anti-tumor activity. The company's proprietary PREDATOR platform not only enhances the safety and dosing flexibility of existing therapies but also shows potential for expanding applications in immune-mediated diseases beyond oncology. With notable clinical achievements from its WTX-124 asset, which has exhibited improved tolerability and a superior safety profile compared to traditional IL-2 therapies, Werewolf Therapeutics is positioned for substantial growth, supporting a positive financial outlook.

Bears say

Werewolf Therapeutics Inc. reported a significant net loss of $20.4 million, or ($0.46) per share, for the fourth quarter of 2024, marking an increase in losses compared to $12.0 million in the same quarter of the previous year. Concerns regarding the future success of the WTX-124 program persist, particularly related to potential clinical or regulatory setbacks, along with doubts about its differentiated safety, efficacy, and pharmacokinetic properties, which could hinder its commercial viability. Additionally, the company's expansion opportunities appear to be undervalued in the broader context of its financial outlook, suggesting that investor sentiment may remain cautious amid these challenges.

Werewolf Therapeutics (HOWL) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 8 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.